Enhabit, Inc. (NYSE:EHAB) Receives Average Rating of “Hold” from Brokerages

Shares of Enhabit, Inc. (NYSE:EHAB) have received a consensus recommendation of “Hold” from the six research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has given a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $8.75.

Several research firms have recently issued reports on EHAB. Jefferies Financial Group upgraded Enhabit from a “hold” rating to a “buy” rating and raised their price target for the stock from $8.25 to $9.50 in a research report on Monday, December 9th. Leerink Partners reissued a “market perform” rating and set a $8.00 price objective (down previously from $8.50) on shares of Enhabit in a research report on Tuesday, November 19th.

Enhabit Price Performance

Shares of NYSE:EHAB opened at $8.52 on Friday. The company has a market capitalization of $428.39 million, a PE ratio of -3.67 and a beta of 1.89. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.46 and a current ratio of 1.46. The company’s fifty day moving average is $7.56 and its 200-day moving average is $8.31. Enhabit has a 52 week low of $6.85 and a 52 week high of $11.74.

Enhabit (NYSE:EHAB) last announced its earnings results on Wednesday, November 6th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). Enhabit had a negative net margin of 11.24% and a positive return on equity of 1.67%. The business had revenue of $253.60 million during the quarter, compared to analyst estimates of $261.69 million. During the same quarter last year, the business posted $0.03 earnings per share. Equities research analysts predict that Enhabit will post 0.22 earnings per share for the current fiscal year.

Insider Buying and Selling at Enhabit

In other news, Director Jeffrey Bolton acquired 4,000 shares of Enhabit stock in a transaction on Thursday, December 12th. The shares were purchased at an average cost of $8.69 per share, for a total transaction of $34,760.00. Following the completion of the purchase, the director now directly owns 98,144 shares of the company’s stock, valued at approximately $852,871.36. This represents a 4.25 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Stuart M. Mcguigan bought 15,000 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was purchased at an average cost of $8.81 per share, for a total transaction of $132,150.00. Following the completion of the acquisition, the director now owns 46,810 shares in the company, valued at approximately $412,396.10. This trade represents a 47.15 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in EHAB. WINTON GROUP Ltd acquired a new position in shares of Enhabit during the second quarter worth $955,000. Marshall Wace LLP bought a new stake in shares of Enhabit during the 2nd quarter valued at about $1,941,000. Systematic Financial Management LP grew its position in shares of Enhabit by 12.2% during the 3rd quarter. Systematic Financial Management LP now owns 1,838,199 shares of the company’s stock worth $14,522,000 after buying an additional 199,235 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in Enhabit in the third quarter worth $215,000. Finally, AREX Capital Management LP increased its position in Enhabit by 2.5% in the 2nd quarter. AREX Capital Management LP now owns 2,472,662 shares of the company’s stock valued at $22,056,000 after buying an additional 59,353 shares in the last quarter.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.